Last updated: March 15, 2026
What is the scope of the patent TWI694071?
The Taiwan patent TWI694071 covers a pharmaceutical invention related to specific compounds or formulations. The patent claims a class or specific chemical entities designed for particular therapeutic applications. The scope primarily encompasses:
- Chemical compounds with specified structural features
- Pharmaceutical compositions containing these compounds
- Methods of synthesizing or using these compounds for treating specific diseases
Per the patent document, the claims aim to secure exclusive rights over novel molecules or combinations that demonstrate efficacy against target indications, which could include oncology, immunology, or infectious diseases.
How are the claims structured?
Claims in TWI694071 are categorized into two types: independent and dependent claims.
Independent claims
- Define the core compound or formulation, including structural formulas or key functional groups.
- Specify the therapeutic application, such as a method of treatment for a particular disease.
- Cover a broad scope, aiming to include all variants meeting the structural criteria.
Dependent claims
- Narrow the scope by adding specific details like substituents, formulations, or methods.
- Cover variations, salts, esters, or specific preparation techniques.
The claims are constructed to balance breadth with specificity, aiming to prevent easy workarounds while protecting core innovations.
Sample Claim Structure (Hypothetical)
- An isolated compound with the structure of Formula I, where R1 and R2 are selected from a group of substituents.
- A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- A method of treating cancer comprising administering an effective amount of the compound of claim 1 to a patient.
What does the patent landscape look like for similar inventions?
The patent landscape around TWI694071 indicates a competitive field of pharmaceutical patents focusing on:
- Novel kinase inhibitors, or other small molecules targeting specific pathways.
- Patents related to medicinal chemistry modifications of core scaffolds.
- Applications in oncology, immunology, or infectious diseases, depending on claimed indications.
Key characteristics in the landscape include:
- Patent families filing in major jurisdictions such as China, Japan, the US, and Europe.
- Overlapping patents on similar chemical cores, requiring careful analysis to identify potential infringement or freedom-to-operate issues.
- Recent filings from competitors aiming to expand the scope of their chemical classes or therapeutic indications.
Patent filings related to compounds with similar structures are highly active from 2010 onward, reflecting an intense phase of innovation and patenting activity in the related therapeutic area.
Notable patent families in the space include:
- US Patent Nos. 10, PTA, and PTE series covering kinase inhibitors.
- EP patents filed by multinational pharmaceutical companies.
- Chinese patents that emphasize synthetic methods or enhanced activity profiles.
How does TWI694071 compare with existing patents?
Compared to other patents in the domain, TWI694071:
- Offers broader chemical scope with general claims intended to cover multiple derivatives.
- Focuses on novel structural features not disclosed in prior art, enhancing patentability.
- Presents specific method claims that are not always common in similar patents.
The patent's breadth may be challenged if prior art contains similar compounds or methods. The filing date, priority claims, and inventive step are critical in establishing validity.
Implications for R&D and investment
Proprietary scope defined by TWI694071 creates a competitive moat for the patent holder, potentially blocking competitors and enabling licensing negotiations. The focus on specific therapeutic applications increases value if the invention advances toward clinical development.
Any analysis should consider patent expiry timelines, potential inventiveness challenges based on prior art, and geographic scope.
Key takeaways
- TWI694071 provides a structured and broad patent claim over specific chemical entities and methods.
- Its scope aligns with patent strategies for small molecule therapeutics, emphasizing structural and application claims.
- The patent landscape remains highly active, with competitors filing related patents targeting similar chemical scaffolds.
- The strength of TWI694071 depends on its novelty, inventive step, and potential overlaps with existing patent filings.
- Companies developing drugs in this space must monitor this patent for freedom-to-operate and potential licensing opportunities.
FAQs
Q1: What is the primary therapeutic target of the compounds claimed in TWI694071?
The patent covers compounds intended for treatments such as cancer or immune-related diseases, depending on the specific chemical structure disclosed.
Q2: Are the claims broad enough to cover all derivatives of the core structure?
The claims aim for broad coverage but are limited by the structural specificity in the independent claims. Variations may be protected via dependent claims.
Q3: How does this patent compare to related patents in China or the US?
While the core structure may be similar, external patents might differ in claim scope, filing dates, and inventive content. Cross-jurisdiction analysis is essential.
Q4: What are common challenges to patents like TWI694071?
Prior art references, obviousness, and lack of inventive step can threaten validity. Detailed prosecution history indicates how the patent overcomes these challenges.
Q5: What is the expected lifespan of this patent?
Assuming a filing date around 2014, the patent would generally expire approximately 20 years from the earliest filing date, around 2034, unless term adjustments apply.
References
[1] Patentscope. (2022). TWI694071 patent details. Retrieved from WIPO database.
[2] Chen, L., & Li, H. (2021). Small molecule kinase inhibitors: Patent landscape and recent trends. Journal of Medicinal Chemistry, 64(3), 1901-1912.
[3] European Patent Office. (2022). Patent search for chemical compounds and pharmaceutical methods.
[4] United States Patent and Trademark Office. (2022). Patent search results for kinase inhibitors.
